Down 99%, biotech firm 180 Life Sciences pivots to crypto with ETH bet
The Nasdaq-listed biotechnology firm is raising $425 million for its ETH strategy, joining a parade of penny stocks investing in cryptocurrencies as their business flounders.
Archive context
Older archive item. Useful for background and entity history, but not a fresh market-moving signal.
The Nasdaq-listed biotechnology firm is raising $425 million for its ETH strategy, joining a parade of penny stocks investing in cryptocurrencies as their business flounders.
Why this matters
This ethereum story adds another data point to the current market tape and is useful when read alongside nearby source coverage.
Original source
Read on CointelegraphRelated market context
Suspicious Kalshi bot shuts down amid wash trading claims
A trading bot making cheap uniform trades on a Zohran Mamdani Kalshi market has stopped trading after it raised suspicions that th...
Jeff Walton: How Strive Supercharged its Bitcoin Buying Strategy
Bitcoin Magazine Jeff Walton: How Strive Supercharged its Bitcoin Buying Strategy Strive was one of the best performing stocks in...
Blockchain.com and NYSE Plan to Bring Tokenized Stocks to 44 Million Crypto Accounts
Blockchain.com plans to offer its users tokenized versions of U.S. exchange-listed stocks and ETFs through the New York Stock Exch...
Coinbase traced $1.1 million crypto trail behind AI phishing service EvilTokens
Microsoft and Coinbase helped dismantle EvilTokens, an AI phishing service tied to more than 12,000 compromised inboxes worldwide....
Coinbase Tracks $1.1M Crypto Trail as Microsoft Takes Down 175 EvilTokens Domains
Key Takeaways: Between October 2025 and June 2026, approximately $1.1 million was traced from several Tron addresses belonging to...
Circle pays millions for Binance distribution while its margins collapse
Circle is doubling down on Binance after USD Coin (USDC) stablecoin customer balances on the exchange nearly quintupled since thei...